Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Colorectal Neoplasms 34Pancreatic Neoplasms 19Colonic Neoplasms 10Rectal Neoplasms 8Stomach Neoplasms 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 7Neoplasms 6Neoplasm Metastasis 6Gastrointestinal Neoplasms 6Esophageal Neoplasms 6Carcinoma, Non-Small-Cell Lung 5Biliary Tract Neoplasms 5Advanced Solid Tumors 4Triple Negative Breast Neoplasms 3Melanoma 3Endometrial Neoplasms 3Carcinoma, Squamous Cell 3Adenocarcinoma Of Esophagus 3Squamous Cell Carcinoma of Head and Neck 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Ovarian Neoplasms 2Liver Neoplasms 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Transitional Cell 2Carcinoma, Hepatocellular 2Carcinoma 2Subjects With Resectable Local or Locally Advanced, Non-Metastatic (T2-T4, N0-N3, M0; Stages II and III) and Histologically-Confirmed Intestinal GC 1Solid Cancer 1Small Cell Lung Carcinoma 1Sarcoma 1

Interventions

pembrolizumab 2atezolizumab 2trastuzumab deruxtecan 1toripalimab 1pertuzumab 1durvalumab 1Trastuzumab 1S-Adenosylmethionine 1Ramucirumab 1Paclitaxel 1Oxaliplatin 1Nivolumab 1Leucovorin 1Irinotecan 1Fluorouracil 1Etoposide 1Cetuximab 1Carboplatin 1Capecitabine 1Bevacizumab 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Solid Cancer × Leucovorin × Clear all
NCT06771622 2026-02-04

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

FBD Biologics Limited

Phase 1/2 Active not recruiting
500 enrolled

Solid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡